CoChat

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Open access

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 14 of the 32 sources its claims cite were checked for support.

Abstract

BACKGROUND: In a phase 1-2 trial, teclistamab, a bispecific antibody targeting CD3 on T-cell surfaces and B-cell maturation antigen on myeloma cells, showed durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. Daratumumab, a monoclonal antibody targeting CD38 protein, has shown survival benefit in patients with multiple myeloma. METHODS: In this phase 3 trial, we randomly assigned patients with one to three previous lines of therapy to receive combination therapy with teclistamab-daratumumab or daratumumab combined with dexamethasone plus the investigator's choice of pomalidomide (DPd) or bortezomib (DVd) - the DPd or DVd group. The primary end point was progression-free survival, as assessed by an independent review committee. RESULTS: ; 58.4% vs. 17.1%) (P<0.001 for all comparisons). Serious adverse events occurred in 70.7% of the patients in the teclistamab-daratumumab group and in 62.4% of those in the DPd or DVd group; death from adverse events occurred in 7.1% and 5.9%, respectively. CONCLUSIONS: In patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free survival than those in the DPd or DVd group. (Funded by Johnson & Johnson; ClinicalTrials.gov number, NCT05083169.).

Overview

CoChat Summary

## TL;DR

MajesTEC-3 is a phase 3 randomized trial in relapsed/refractory multiple myeloma showing that teclistamab plus daratumumab (Tec-Dara) improved progression-free survival and overall survival versus standard daratumumab-based care. The combination also increased response depth and MRD negativity, but it came with frequent adverse events, including infections and treatment-emergent fatal events.

## Key findings

  • 587 patients were randomized (Tec-Dara, n=291; DPd/DVd, n=296); median follow-up was 34.5 months.
  • Estimated 36-month progression-free survival was 83.4% with Tec-Dara versus 29.7% with DPd/DVd; HR 0.17 (95% CI, 0.12–0.23; P<0.0001).
  • Complete response or better occurred in 81.8% vs. 32.1%, overall response in 89.0% vs. 75.3%, and MRD negativity at 10^-5 in 58.4% vs. 17.1% with Tec-Dara vs. DPd/DVd, all significantly favored Tec-Dara.
  • Estimated 36-month overall survival was 83.3% with Tec-Dara and 65.0% with DPd/DVd (P<0.0001); time to worsening of symptoms also favored Tec-Dara (36-month event-free rate 75.6% vs. 63.3%; HR 0.50).
  • Safety was substantial in both groups: grade 3/4 adverse events occurred in 95.1% vs. 96.6%, deaths due to treatment-emergent adverse events in 7.1% vs. 5.9%, and grade 3/4 infections in 54.1% vs. 43.4% with Tec-Dara vs. DPd/DVd.

## Methods

  • Multicenter, open-label, phase 3 randomized study across 150 sites in 20 countries; patients were randomized 1:1 to Tec-Dara or investigator’s choice of DPd/DVd.
  • Eligible patients had 1–3 prior lines of antimyeloma therapy, including a proteasome inhibitor and lenalidomide, with progression on or after the last regimen; key exclusions included prior BCMA-directed therapy and anti-CD38 refractoriness.
  • Primary endpoint was progression-free survival by blinded independent review committee; key secondary endpoints included ≥CR, overall response, MRD negativity, overall survival, and symptom worsening; analyses used stratified log-rank tests, Cox models, and hierarchical testing.

## Limitations

  • The paper states that the width of confidence intervals was not adjusted for multiplicity and “may not be used in place of hypothesis testing.”
  • The paper notes that subgroup findings for prior anti-CD38 exposure, age >75 years, and ECOG performance status 2 were based on “a few patients” or “small” subgroups; this limits certainty in those strata.
  • Evident from the text: the study was open-label, which can introduce bias in subjective outcomes such as symptom reporting.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1056/nejmoa2514663

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Progression-Free Survival. Panel A shows Kaplan-Meier estimates of progression-free (PFS) survival among patients who were randomized to receive teclistamab in combination with daratumumab (Tec-Dara) or investigator’s choice of daratumumab in combination with dexamethasone and either pomalidomide or bortezomib (DPd/DVd); red shading indicates the 95% CI for the Tec-Dara group and grey shading the 95% CI for the DPd/DVd group; tick marks indicate censored data. At a median follow-up of 34.5 months, median PFS was not reached in the Tec-Dara group and was 18.1 months in the DPd/DVd group, therefore favoring Tec-Dara treatment. Panel B shows the results of a prespecified subgroup analysis of PFS in the intent-to-treat population. The International Staging System (ISS) consists of 3 stages, with a higher stage indicating more severe disease, and is derived based on serum beta-2-microglobulin and albumin. High cytogenetic risk is defined by fluorescence in situ hybridization or karyotype testing of patients having t(4;14), t(14;16), or del(17p). Eastern Cooperative Oncology Group (ECOG) performance status score ranges from 0 to 5, with higher scores indicating greater disability. Baseline soft-tissue plasmacytomas contains both extramedullary and paraskeletal plasmacytomas. Hazard ratio of <1.0 indicates an advantage for teclistamab in combination with daratumumab versus investigator’s choice (daratumumab in combination dexamethasone and either pomalidomide or bortezomib). Note, CI widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing. Further, the following subgroup analyses presented in Panel B were post-hoc: region, prior exposure to anti-CD38, and refractory status to lenalidomide. CI denotes confidence interval.
Figure 1. Progression-Free Survival. Panel A shows Kaplan-Meier estimates of progression-free (PFS) survival among patients who were randomized to receive teclistamab in combination with daratumumab (Tec-Dara) or investigator’s choice of daratumumab in combination with dexamethasone and either pomalidomide or bortezomib (DPd/DVd); red shading indicates the 95% CI for the Tec-Dara group and grey shading the 95% CI for the DPd/DVd group; tick marks indicate censored data. At a median follow-up of 34.5 months, median PFS was not reached in the Tec-Dara group and was 18.1 months in the DPd/DVd group, therefore favoring Tec-Dara treatment. Panel B shows the results of a prespecified subgroup analysis of PFS in the intent-to-treat population. The International Staging System (ISS) consists of 3 stages, with a higher stage indicating more severe disease, and is derived based on serum beta-2-microglobulin and albumin. High cytogenetic risk is defined by fluorescence in situ hybridization or karyotype testing of patients having t(4;14), t(14;16), or del(17p). Eastern Cooperative Oncology Group (ECOG) performance status score ranges from 0 to 5, with higher scores indicating greater disability. Baseline soft-tissue plasmacytomas contains both extramedullary and paraskeletal plasmacytomas. Hazard ratio of <1.0 indicates an advantage for teclistamab in combination with daratumumab versus investigator’s choice (daratumumab in combination dexamethasone and either pomalidomide or bortezomib). Note, CI widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing. Further, the following subgroup analyses presented in Panel B were post-hoc: region, prior exposure to anti-CD38, and refractory status to lenalidomide. CI denotes confidence interval.CC BY-NC-ND · PubMed Central
Figure 2. Overall Survival. Figure shows Kaplan-Meier estimates of overall survival (OS) among patients who were randomized to receive teclistamab in combination with daratumumab (Tec-Dara), or investigator’s choice of daratumumab in combination with dexamethasone and either pomalidomide or bortezomib (DPd/DVd); red shading indicates the 95% CI for the Tec-Dara group and grey shading the 95% CI for the DPd/DVd group; tick marks indicate censored data. At a median follow-up of 34.5 months, treatment effect on OS significantly favored Tec-Dara versus DPd/DVd. P value is based on the log-rank test stratified with International Staging System stage (I vs. II or III) and number of prior lines (1 vs. 2 or 3), as randomized. Of note, fatal infections occurred in 13 patients in the Tec-Dara group and 4 patients in the DPd/DVd group. Twelve of the 13 infection-related deaths with Tec-Dara took place before the implementation of Protocol Amendment 6, which included reinforced immunoglobulin guidance; 1 infection-related death was reported thereafter. Note, CI widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing. CI denotes confidence interval.
Figure 2. Overall Survival. Figure shows Kaplan-Meier estimates of overall survival (OS) among patients who were randomized to receive teclistamab in combination with daratumumab (Tec-Dara), or investigator’s choice of daratumumab in combination with dexamethasone and either pomalidomide or bortezomib (DPd/DVd); red shading indicates the 95% CI for the Tec-Dara group and grey shading the 95% CI for the DPd/DVd group; tick marks indicate censored data. At a median follow-up of 34.5 months, treatment effect on OS significantly favored Tec-Dara versus DPd/DVd. P value is based on the log-rank test stratified with International Staging System stage (I vs. II or III) and number of prior lines (1 vs. 2 or 3), as randomized. Of note, fatal infections occurred in 13 patients in the Tec-Dara group and 4 patients in the DPd/DVd group. Twelve of the 13 infection-related deaths with Tec-Dara took place before the implementation of Protocol Amendment 6, which included reinforced immunoglobulin guidance; 1 infection-related death was reported thereafter. Note, CI widths have not been adjusted for multiplicity and may not be used in place of hypothesis testing. CI denotes confidence interval.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

9 Valid · 3 Not valid · 4 Not checked · 51 Own results and interpretations

23 more claims

Create a free account to see all 67 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 21
  • Probably not a substantial claim. 26
  • Borderline: one of the tests for a substantial claim is unclear. 1

Create a free account to see these claims.

Citations

Cites

Cited by

See all 119

Metadata

Authors
Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., Reece, D., Niu, T., Mylin, A. K., Hansen, C. T., Teipel, R., Besemer, B., Dimopoulos, M. A., Zamagni, E., Yoshihara, S., Kim, K., Min, C. K., Geerts, P., Van Leeuwen-Segarceanu, E., Tyczynska, A., Reguera, J. L., Johansson, M., Hansson, M., Turgut, M., Grey, M., Sidana, S., Rodriguez-Otero, P., Martinez-Lopez, J., Hashmi, H., Carson, R., Kobos, R., Sun, W., Lantz, K., Seifert, A., Briseno-Toomey, D., O’Rourke, L., Rubin, M., Vieyra, D., Kang, L., & Mateos, M. V.
Affiliations
  • University of Alabama at Birmingham (US)
  • University of Calgary (CA)
  • Centre Hospitalier Universitaire de Toulouse (FR)
  • Winship Cancer Institute (US)
  • Peking University People's Hospital (CN)
  • Royal Marsden NHS Foundation Trust (GB)
  • Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
  • Hospital Privado Universitario de Córdoba Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina
  • Hôpital de Jolimont (BE)
  • Clinica São Germano, São Paulo
  • Princess Margaret Cancer Centre (CA)
  • Sichuan University (CN)
  • Rigshospitalet (DK)
  • Odense University Hospital (DK)
  • University Hospital Carl Gustav Carus (DE)
  • University of Tübingen (DE)
  • Korea University (KR)
  • Istituto di Ematologia di Bologna (IT)
  • Hyogo Medical University Hospital (JP)
  • Division of Hematology–Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea
  • The Catholic University of Korea Seoul St. Mary's Hospital (KR)
  • Isala (NL)
  • St. Antonius Ziekenhuis (NL)
  • Department of Hematology and Transplantology, Medical University of Gdansk; Department of Hematology and Transplantology, University Clinical Center, Gdansk, Poland
  • Instituto de Biomedicina de Sevilla (ES)
  • Sunderby sjukhus (SE)
  • Sahlgrenska University Hospital (SE)
  • Ondokuz Mayıs University (TR)
  • Blackpool Victoria Hospital (GB)
  • Stanford Medicine (US)
  • Cancer Center Clínica Universidad de Navarra, Pamplona, Spain
  • Hematology Department, Instituto de Investigación Hospital 12 de Octubre, Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, Centro de Investigación Biomédica en Red de Cáncer, Madrid
  • Memorial Sloan Kettering Cancer Center (US)
  • Johnson & Johnson (United States) (US)
  • Johnson & Johnson (United Kingdom) (GB)
  • Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer (Universidad de Salamanca–Consejo Superior de Investigaciones Científicas), Centro de Investigación Biomédica en Red de Cáncer, Salamanca, Spain
Venue
New England Journal of Medicine
Published
2026-02-19
Volume
394
Issue
8
Pages
739-752
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4417156840
Cited by
119
References
35
Citations by year
2026: 117
FWCI
81.61
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (acceptedVersion, other-oa)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Funders
Johnson & Johnson
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
teclistamab, daratumumab, relapsed/refractory multiple myeloma, bispecific antibodies, CD38, progression-free survival, dexamethasone, pomalidomide, bortezomib, combination therapy, adverse events
MeSH terms
Bortezomib, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Multiple Myeloma, Neoplasm Recurrence, Local, Thalidomide, Time Factors, Antibodies, Bispecific, Drug Resistance, Neoplasm, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.